Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 403,815 | 434,215 | 470,783 | 662,205 | 660,672 |
| Marketable Securities | 1,208,887 | 1,362,017 | 404,695 | 334,473 | 459,533 |
| Receivables | 489,017 | 494,645 | 423,537 | 419,424 | 392,672 |
| Inventories | 780,517 | 719,316 | 572,239 | 622,253 | 554,007 |
| Other current assets | 26,054 | 23,604 | 10,089 | 10,859 | 10,940 |
| TOTAL | $3,048,330 | $3,157,976 | $1,990,479 | $2,139,835 | $2,180,155 |
| Non-Current Assets | |||||
| PPE Net | 529,007 | 498,612 | 511,639 | 491,371 | 499,339 |
| Investments And Advances | 7,698,070 | 8,830,892 | 14,387,010 | 9,561,140 | 4,638,205 |
| Intangibles | 734,083 | 738,635 | 601,282 | 491,413 | 409,656 |
| Other Non-Current Assets | 289,580 | 275,551 | 308,979 | 288,856 | 281,505 |
| TOTAL | $9,250,740 | $10,343,690 | $15,808,910 | $10,832,780 | $5,828,705 |
| Total Assets | $12,299,070 | $13,501,670 | $17,799,390 | $12,972,620 | $8,008,859 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 486 | 465 | 489 | 1,798 | 426,172 |
| Accounts payable and accrued liabilities | 144,625 | 135,041 | 141,941 | 139,451 | 107,014 |
| Accrued Expenses | 139,929 | 194,790 | 276,986 | 222,875 | 180,084 |
| Other current liabilities | 161,621 | 169,648 | 127,936 | 131,102 | 86,840 |
| TOTAL | $522,799 | $568,708 | $680,938 | $631,536 | $905,495 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,199,052 | 1,197,716 | 10,514 | 12,258 | 13,579 |
| Deferred Revenues | N/A | N/A | 50,852 | 42,468 | 33,735 |
| aiOther Non-Current Liabilities | 360,591 | 349,509 | 358,129 | 372,099 | 336,941 |
| TOTAL | $3,035,138 | $3,317,706 | $3,433,219 | $2,461,142 | $1,348,307 |
| Total Liabilities | $3,557,937 | $3,886,414 | $4,114,157 | $3,092,678 | $2,253,802 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,518 | 29,596 | 29,932 | 29,844 | 29,925 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 9,260,629 | 9,898,203 | 13,525,340 | 9,268,012 | 5,470,779 |
| Other shareholders' equity | -335,574 | -466,408 | -175,836 | 282,549 | -87,745 |
| TOTAL | $8,741,133 | $9,615,252 | $13,685,240 | $9,879,940 | $5,755,057 |
| Total Liabilities And Equity | $12,299,070 | $13,501,666 | $17,799,397 | $12,972,618 | $8,008,859 |